With a PEG of only .70 and earnings of 9 dollars per share with a market cap on only 10 billion and doing business in another county with all the recent buyouts and a blockbuster drug with 30 on the way to the FDA this will get bought for over 200 a share
Anything below 1.00 Some things to ponder
Here are a few more interesting tidbits from my study:
92% of companies with PEG ratios of less than 1 beat the market over three years.
68% of companies with PEG ratios of between 1 and 2 beat the market.
47% of companies with PEG ratios greater than 2 beat the market.
The best performer was (surprise, surprise) Hansen Natural (Nasdaq: HANS ) . It had a PEG of 0.08 in 2003 and had gained 5,400% through March.
The second-best performer was NutriSystem (Nasdaq: NTRI ) with a PEG of 0.06 and a gain of 5,200%.
Despite a PEG of 0.55, Ford (NYSE: F ) managed only a 14% gain over three years.
#$%$ Sporting Goods (NYSE: DKS ) was "fairly valued" with a PEG of exactly 1, but it still appreciated by 265%.
A PEG of 8 didn't stop Select Comfort (Nasdaq: SCSS ) from appreciating by 266%.
Canaccord Genuity took the other route, raising its price target to $150 from $145 based on higher market share for the iPhone 6.
Read more: Top Analyst Upgrades and Downgrades: Apple, Citrix, Kythera, Mylan, Netflix, Weatherford and More - Apple Inc. (NASDAQ:AAPL) - 24/7 Wall St. http://247wallst.com/investing/2015/04/10/top-analyst-upgrades-and-downgrades-apple-citrix-kythera-mylan-netflix-weatherford-and-more/#ixzz3WuWmJApd
Follow us: @247wallst on Twitter | 247wallst on Fac
A source familiar with the matter told Benzinga Tuesday that Mallinckrodt PLC (NYSE: MNK) was in talks to acquire Insys Therapeutics Inc(NASDAQ: INSY) in a transaction valuing shares at around $65.
Shares of Insys were trading higher by more than 6 percent Wednesday.
Speaking to Benzinga on Wednesday, Oppenheimer analyst Akiva Felt said that progression of rumor between the two companies is "still stagnant," but he added that it "fits into" Mallinckrodt's strategy.
The analyst also added that he "doesn't know why it would be more likely now versus four months ago."
Finally, when asked if a consolidation is expected between large biotech companies and smaller cannabis companies, Felt suggested that analysts are "talking down" on M&A chatter of that magnitude.